Mark Andrew Ainsworth

Mark Andrew Ainsworth is a Clinical Professor at the Karolinska Institute and a Senior Consultant at Odense University Hospital (OUH) within the Research Unit of Medical Gastroenterology in Odense. He also holds external positions such as Chief Medical Officer at the Danish Medicines Agency and Head of Department at Herlev and Gentofte Hospital, with a secondary appointment as an Associate Clinical Professor at the University of Copenhagen.

• Primary Affiliation: Department of Clinical Research, Karolinska Institute
• Secondary Affiliation: Research Unit of Medical Gastroenterology (Odense), OUH
• External Roles: Chief Medical Officer (Danish Medicines Agency), Head of Department (Herlev and Gentofte Hospital)

Ainsworth’s research focuses on Inflammatory Bowel Disease (IBD), particularly Crohn's Disease and Ulcerative Colitis, with expertise in Therapeutic Antibodies, Immunogenicity, and Collagen Degradation. His work spans pharmacology, clinical treatment strategies, and biomarker discovery.

Recent publications highlight trends in IBD research, including biological therapies (e.g., filgotinib, mirikizumab), drug immunogenicity, and neutrophil-driven tissue damage during colitis. These papers emphasize clinical translation and real-world treatment outcomes.

Scientific Contributions include foundational datasets on sodium bicarbonate cotransporters and Na+/H+ exchangers from the 1999 studies, alongside ongoing IBD research.

• Supervision: PhD students Camilla Frimor (2024–2027) and Thomai Tsapanou Katranara (2023–2026)
• Teaching: Courses on medical journals and regulatory agency requirements (2023–2024)